PMC:7216762 / 6606-7785 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":650,"end":658},"obj":"Body_part"},{"id":"T7","span":{"begin":829,"end":837},"obj":"Body_part"},{"id":"T8","span":{"begin":888,"end":897},"obj":"Body_part"},{"id":"T9","span":{"begin":922,"end":935},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma9825"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":922,"end":935},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002405"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T17","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"T18","span":{"begin":401,"end":409},"obj":"Disease"},{"id":"T19","span":{"begin":534,"end":542},"obj":"Disease"},{"id":"T20","span":{"begin":682,"end":702},"obj":"Disease"},{"id":"T21","span":{"begin":693,"end":702},"obj":"Disease"},{"id":"T22","span":{"begin":733,"end":741},"obj":"Disease"}],"attributes":[{"id":"A17","pred":"mondo_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A18","pred":"mondo_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A19","pred":"mondo_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A20","pred":"mondo_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A21","pred":"mondo_id","subj":"T21","obj":"http://purl.obolibrary.org/obo/MONDO_0005578"},{"id":"A22","pred":"mondo_id","subj":"T22","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T37","span":{"begin":637,"end":638},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T38","span":{"begin":922,"end":935},"obj":"http://purl.obolibrary.org/obo/UBERON_0002405"},{"id":"T39","span":{"begin":1016,"end":1017},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T7","span":{"begin":50,"end":55},"obj":"Chemical"},{"id":"T8","span":{"begin":382,"end":386},"obj":"Chemical"},{"id":"T9","span":{"begin":446,"end":450},"obj":"Chemical"},{"id":"T10","span":{"begin":790,"end":792},"obj":"Chemical"},{"id":"T12","span":{"begin":1132,"end":1136},"obj":"Chemical"}],"attributes":[{"id":"A7","pred":"chebi_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A8","pred":"chebi_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A9","pred":"chebi_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A10","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A11","pred":"chebi_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A12","pred":"chebi_id","subj":"T12","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":682,"end":702},"obj":"Phenotype"},{"id":"T2","span":{"begin":829,"end":844},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0033041"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-sentences","denotations":[{"id":"T46","span":{"begin":0,"end":15},"obj":"Sentence"},{"id":"T47","span":{"begin":16,"end":174},"obj":"Sentence"},{"id":"T48","span":{"begin":175,"end":623},"obj":"Sentence"},{"id":"T49","span":{"begin":624,"end":761},"obj":"Sentence"},{"id":"T50","span":{"begin":762,"end":967},"obj":"Sentence"},{"id":"T51","span":{"begin":968,"end":1179},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}

{"project":"LitCovid-PubTator","denotations":[{"id":"55","span":{"begin":153,"end":161},"obj":"Disease"},{"id":"61","span":{"begin":410,"end":418},"obj":"Species"},{"id":"62","span":{"begin":543,"end":551},"obj":"Species"},{"id":"63","span":{"begin":387,"end":397},"obj":"Chemical"},{"id":"64","span":{"begin":401,"end":409},"obj":"Disease"},{"id":"65","span":{"begin":534,"end":542},"obj":"Disease"},{"id":"71","span":{"begin":790,"end":794},"obj":"Gene"},{"id":"72","span":{"begin":742,"end":750},"obj":"Species"},{"id":"73","span":{"begin":624,"end":635},"obj":"Chemical"},{"id":"74","span":{"begin":682,"end":702},"obj":"Disease"},{"id":"75","span":{"begin":733,"end":741},"obj":"Disease"}],"attributes":[{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C000657245"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"Tax:9606"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"Tax:9606"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000606551"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C000657245"},{"id":"A65","pred":"tao:has_database_id","subj":"65","obj":"MESH:C000657245"},{"id":"A71","pred":"tao:has_database_id","subj":"71","obj":"Gene:3569"},{"id":"A72","pred":"tao:has_database_id","subj":"72","obj":"Tax:9606"},{"id":"A73","pred":"tao:has_database_id","subj":"73","obj":"MESH:C502936"},{"id":"A74","pred":"tao:has_database_id","subj":"74","obj":"MESH:D001172"},{"id":"A75","pred":"tao:has_database_id","subj":"75","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Clinical Trials\nThe two most promising repurposed drugs that have been used during the current emergency are now entering legitimate clinical trials for COVID-19, as follows.\nThe Italian Drug Association (AIFA) and Gilead have recently announced that Italy will take part in two Phase III clinical trials that will allow an assessment of the efficacy and safety of the experimental drug Remdesivir in COVID-19 patients.5 As mentioned above, this drug is currently being administered “for compassionate use” for emergency treatment of COVID-19 patients in critical condition that do not have alternative therapeutic options.\nTocilizumab, a monoclonal antibody developed for treating rheumatoid arthritis, was first used to treat some COVID-19 patients in Naples. It inhibits the receptor of IL-6, likely damping the effect of the cytokine storms (i.e., massive release of pro-inflammatory cytokines that overstimulates the immune system) observed in more severe cases. Today, AIFA swiftly authorized the beginning of a clinical trial,6 involving many hospitals in Italy, that was made possible also by Roche committing to supply the drug for free for the whole emergency duration."}